Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study

被引:301
作者
Giaccone, Giuseppe [1 ]
Kim, Chul [1 ]
Thompson, Jillian [1 ]
McGuire, Colleen [1 ]
Kallakury, Bhaskar [1 ]
Chahine, Joeffrey J. [1 ]
Manning, Maria [1 ]
Mogg, Robin [2 ]
Blumenschein, Wendy M. [2 ]
Tan, Ming T. [1 ]
Subramaniam, Deepa S. [1 ]
Liu, Stephen V. [1 ]
Kaplan, Ian M. [3 ]
McCutcheon, Justine N. [1 ]
机构
[1] Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC USA
[2] Merck & Co Inc, Kenilworth, NJ USA
[3] Adapt Biotechnol, Seattle, WA USA
关键词
CELL LUNG-CANCER; EPITHELIAL TUMORS; PD-1; BLOCKADE; SOLID TUMORS; OPEN-LABEL; THYMOMA; CHEMOTHERAPY; MALIGNANCIES; EXPRESSION; NEOPLASMS;
D O I
10.1016/S1470-2045(18)30062-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Treatment options are limited for patients with thymic carcinoma. These aggressive tumours are not typically associated with paraneoplastic autoimmune disorders, and strong PD-L1 expression has been reported in thymic epithelial tumours. We aimed to assess the activity of pembrolizumab, a monoclonal antibody that targets PD-1, in patients with advanced thymic carcinoma. Methods We completed a single-arm phase 2 study of pembrolizumab in patients with recurrent thymic carcinoma who had progressed after at least one line of chemotherapy. This was a single-centre study performed at Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. Key inclusion criteria were an Eastern Cooperative Oncology Group performance status of 0-2, no history of autoimmune disease or other malignancy requiring treatment or laboratory abnormality, and adequate organ function. Patients received 200 mg of pembrolizumab every 3 weeks for up to 2 years. The primary objective of the study was the proportion of patients who had achieved a response assessed with Response Evaluation Criteria in Solid Tumors version 1.1. Analysis was per protocol, in all eligible patients. The study is registered with ClinicalTrials. gov, number NCT02364076, and is closed to accrual; we report the final analysis. Findings 41 patients were enrolled from March 12, 2015, to Dec 16, 2016, of whom 40 were eligible and evaluable and one was excluded because of elevated liver enzymes at screening. The median follow-up was 20 months (IQR 14-26). The proportion of patients who achieved a response was 22.5% (95% CI 10.8-38.5); one (3%) patient achieved a complete response, eight (20%) patients achieved partial responses, and 21 (53%) patients achieved stable disease. The most common grade 3 or 4 adverse events were increased aspartate aminotransferase and alanine aminotransferase (five [13%] patients each). Six (15%) patients developed severe autoimmune toxicity, including two (5%) patients with myocarditis. There were 17 deaths at the time of analysis, but no deaths due to toxicity. Interpretation Pembrolizumab is a promising treatment option in patients with thymic carcinoma. Because severe autoimmune disorders are more frequent in thymic carcinoma than in other tumour types, careful monitoring is essential.
引用
收藏
页码:347 / 355
页数:9
相关论文
共 32 条
[1]  
[Anonymous], 2012, Gynecologic cancers portfolio
[2]   IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade [J].
Ayers, Mark ;
Lunceford, Jared ;
Nebozhyn, Michael ;
Murphy, Erin ;
Loboda, Andrey ;
Kaufman, David R. ;
Albright, Andrew ;
Cheng, Jonathan D. ;
Kang, S. Peter ;
Shankaran, Veena ;
Piha-Paul, Sarina A. ;
Yearley, Jennifer ;
Seiwert, Tanguy Y. ;
Ribas, Antoni ;
McClanahan, Terrill K. .
JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (08) :2930-2940
[3]   Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia [J].
Burbelo, Peter D. ;
Browne, Sarah K. ;
Sampaio, Elizabeth P. ;
Giaccone, Giuseppe ;
Zaman, Rifat ;
Kristosturyan, Ervand ;
Rajan, Arun ;
Ding, Li ;
Ching, Kathryn H. ;
Berman, Arlene ;
Oliveira, Joao B. ;
Hsu, Amy P. ;
Klimavicz, Caitlin M. ;
Iadarola, Michael J. ;
Holland, Steven M. .
BLOOD, 2010, 116 (23) :4848-4858
[4]   A phase II study of pembrolizumab for patients with previously treated advanced thymic epithelial tumor. [J].
Cho, Jinhyun ;
Ahn, Myung-Ju ;
Yoo, Kwai Han ;
Lee, Hansang ;
Kim, Hee Kyung ;
Heo, Mi Hwa ;
Hong, Joo Hyun ;
Sun, Jong-Mu ;
Lee, Se-Hoon ;
Ahn, Jin Seok ;
Park, Keunchil .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[5]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[6]   Epidemiology of Thymoma and Associated Malignancies [J].
Engels, Eric A. .
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 :S260-S265
[7]   Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial [J].
Fehrenbacher, Louis ;
Spira, Alexander ;
Ballinger, Marcus ;
Kowanetz, Marcin ;
Vansteenkiste, Johan ;
Mazieres, Julien ;
Park, Keunchil ;
Smith, David ;
Artal-Cortes, Angel ;
Lewanski, Conrad ;
Braiteh, Fadi ;
Waterkamp, Daniel ;
He, Pei ;
Zou, Wei ;
Chen, Daniel S. ;
Yi, Jing ;
Sandler, Alan ;
Rittmeyer, Achim .
LANCET, 2016, 387 (10030) :1837-1846
[8]   Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer [J].
Garon, Edward B. ;
Rizvi, Naiyer A. ;
Hui, Rina ;
Leighl, Natasha ;
Balmanoukian, Ani S. ;
Eder, Joseph Paul ;
Patnaik, Amita ;
Aggarwal, Charu ;
Gubens, Matthew ;
Horn, Leora ;
Carcereny, Enric ;
Ahn, Myung-Ju ;
Felip, Enriqueta ;
Lee, Jong-Seok ;
Hellmann, Matthew D. ;
Hamid, Omid ;
Goldman, Jonathan W. ;
Soria, Jean-Charles ;
Dolled-Filhart, Marisa ;
Rutledge, Ruth Z. ;
Zhang, Jin ;
Lunceford, Jared K. ;
Rangwala, Reshma ;
Lubiniecki, Gregory M. ;
Roach, Charlotte ;
Emancipator, Kenneth ;
Gandhi, Leena .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21) :2018-2028
[9]   Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy [J].
Heinzerling, Lucie ;
Ott, Patrick A. ;
Hodi, F. Stephen ;
Husain, Aliya N. ;
Tajmir-Riahi, Azadeh ;
Tawbi, Hussein ;
Pauschinger, Matthias ;
Gajewski, Thomas F. ;
Lipson, Evan J. ;
Luke, Jason J. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
[10]   Fulminant Myocarditis with Combination Immune Checkpoint Blockade [J].
Johnson, Douglas B. dbj ;
Balko, Justin M. jmb ;
Compton, Margaret L. mlc ;
Chalkias, Spyridon sc ;
Gorham, Joshua jc ;
Xu, Yaomin yx ;
Hicks, Mellissa mh ;
Puzanov, Igor ip ;
Alexander, Matthew R. mra ;
Bloomer, Tyler L. tlb ;
Becker, Jason R. jrb ;
Slosky, David A. das ;
Phillips, Elizabeth J. ejp ;
Pilkinton, Mark A. map ;
Craig-Owens, Laura lco ;
Kola, Nina nk ;
Plautz, Gregory gp ;
Reshef, Daniel S. dsr ;
Deutsch, Jonathan S. jsd ;
Deering, Raquel P. rpd ;
Olenchock, Benjamin A. bao ;
Lichtman, Andrew H. ahl ;
Roden, Dan M. dmr ;
Seidman, Christine E. ces ;
Koralnik, Igor J. ijk ;
Seidman, Jonathan G. jgs ;
Hoffman, Robert D. rdh ;
Taube, Janis M. jmt ;
Diaz, Luis A. Jr lad ;
Anders, Robert A. raa ;
Sosman, Jeffrey A. jas ;
Moslehi, Javid J. jjm .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18) :1749-1755